Free Lesson Preview
This is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Free GCP training
Professional tracks
Clinical Research Coordinator
Full course · Study Start-Up and Site Activation
Free Lesson Preview
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Analyze the competitive study landscape at the site level, assess therapeutic area saturation, and apply a structured accept/defer/decline framework when studies compete for the same resources and patients.
The site has just been awarded a Phase III nonalcoholic steatohepatitis (NASH) trial. The protocol is complex -- liver biopsies, quarterly MRI-PDFF imaging, a 72-week treatment period -- but the investigator is excited and the patient pool looks adequate. Enrollment is expected to begin in two months. Then, within a single week, two more NASH study opportunities arrive from competing sponsors. Different molecules, similar mechanisms of action, nearly identical eligibility criteria, and overlapping enrollment timelines.
Your patient pool has not grown. Your coordinator hours have not multiplied. Your investigator's Wednesday afternoons have not expanded. But the number of studies competing for those finite resources just tripled.
This is not a hypothetical problem. It is Tuesday. And the question the site must answer -- honestly, rigorously, before any feasibility questionnaire is returned -- is not "Can we do all three?" It is: "What happens to each study, and to our existing commitments, if we try?"
I have watched this scenario unfold dozens of times, across therapeutic areas from oncology to metabolic disease to CNS. And the sites that handle it well share one characteristic: they treat their study portfolio the way an honest financial advisor treats an investment portfolio. They diversify. They know their capacity limits. And when a new opportunity arrives that would overextend the portfolio, they say so -- clearly, early, and with data.
The sites that handle it poorly share a different characteristic. They say yes to everything. Not out of dishonesty, but out of optimism -- a genuine belief that they will find the patients, find the time, make it work. And then enrollment lags across all three studies, protocol deviations accumulate, the coordinator burns out, and the site's reputation suffers in ways that take years to repair.
This lesson teaches you how to analyze competing study demands systematically, recognize when your therapeutic area portfolio has reached saturation, and make structured decisions about whether to accept, defer, or decline a new study opportunity.
What you will learn4 objectives
By the end of this lesson, you will be able to:
Progress saves itself — finish reading and this lesson completes